Stockreport

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases [Yahoo! Finance]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Expand bexobrutideg into autoimmune and inflammatory indications, targeting IND submission in 2026 with a new tablet formulation Advance a growing portfolio of partne [Read more]